This course provides a full introduction to preclinical safety testing relating to regulations and guidelines in Europe (national, CHMP, ICH level). The course faculty is European-based leading experts in preclinical safety testing and safety sciences. Topics will be presented through interactive lecture and hands-on workshop training methods, with an emphasis on practical application of the regulations and guidelines pertinent to preclinical and clinical medicines development and registration. The content for this course focuses on development of small molecule medicines and biologically-derived medicines.
- Role of preclinical safety studies in medicines development and registration in Europe
- Outline of preclinical medicines discovery and development, regulatory and industry perspectives
- Translational aspects of preclinical safety sciences, including safety biomarkers
- Scope and type of preclinical safety studies and timing to clinical development and registration
- Contemporary scientific and regulatory topics of interest: environmental risk assessment, single and repeat dose toxicity, establishing first human dose, juvenile animals studies, safety pharmacology, toxicity to the immune system, genotoxicity carcinogenicity testing, pharmaco-toxicokinetics, metabolism, reproduction toxicology protocols and interpretation for pregnancy labelling of pharmaceuticals, when mechanistic studies are needed, impurities and others
- Specific aspects of, e.g., vaccines, anticancer medicines, biotechnology-derived medicines
- The Common Technical Document and Assessment Report
structures in Europe may be included on case-by-case basis
The “Non-Clinical Safety Sciences and Their Regulatory Aspects” training course has been accredited with 5 ECTS credits by the University of Lisbon, Portugal.
Who should attend?
At the conclusion of this course, participants should be able to:
- Discuss the scope and needs for preclinical safety programs in relation to clinical trials in Europe
- Discuss calculations of First-In-Human doses
- Identify requirements for successful preclinical medicines development in Europe
- Describe European culture and complexity in the registration system
- Explain the fundamentals of preclinical medicines development in Europe, and in ICH environment
- Share recent real world experiences of preclinical medicines development agencies and companies in Europe